Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III nintedanib plus best supportive care versus placebo plus best supportive care in refractory metastatic colorectal cancer
NL-OMON42006Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nintedanib in colorectal adenocarcinoma and metastatic colorectal adenocarcinoma (mCRC), sponsored by Boehringer Ingelheim. Started Nov 2014; status: active, not recruiting.
02
Drugs
nintedanib
03
Conditions
colorectal adenocarcinomametastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on NL-OMON42006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42006.